Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

We haven't written up this one. CNBC has the full story — the link below goes straight to it.

Read the original at cnbc.com →

More in Health & Medicine

More from Thursday 20 August →